Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 209 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Celebrating 10 years of partnership with NIVEA Sun October 14, 2022 EMA Recommends Extension of Indications for Trastuzumab Deruxtecan July 21, 2022 Identical Twins Get Mirror Cancer Diagnoses Within Three Weeks Of Each... August 15, 2019 Breast-Cancer Mom Is Living On 84 Pence As She Fights For... April 15, 2019 Load more HOT NEWS Five Questions with…Fred. Whole-Genome Sequencing Could Help Guide AML Treatment Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and... Olivia Newton-John Shares Positive News On Breast Cancer: “I’m Winning Over...
